CY1120039T1 - Ογκολυτικοι αδενοϊικοι φορεις και μεθοδοι και χρησεις οι οποιες σχετιζονται με αυτους - Google Patents
Ογκολυτικοι αδενοϊικοι φορεις και μεθοδοι και χρησεις οι οποιες σχετιζονται με αυτουςInfo
- Publication number
- CY1120039T1 CY1120039T1 CY20171100126T CY171100126T CY1120039T1 CY 1120039 T1 CY1120039 T1 CY 1120039T1 CY 20171100126 T CY20171100126 T CY 20171100126T CY 171100126 T CY171100126 T CY 171100126T CY 1120039 T1 CY1120039 T1 CY 1120039T1
- Authority
- CY
- Cyprus
- Prior art keywords
- relates
- subject
- present
- methods
- adhesive
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000853 adhesive Substances 0.000 title 1
- 230000001070 adhesive effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 239000013598 vector Substances 0.000 abstract 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 239000000969 carrier Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000037455 tumor specific immune response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20080671A FI20080671A0 (fi) | 2008-12-22 | 2008-12-22 | Onkolyyttiset virukset |
| FI20095466A FI121508B (fi) | 2008-12-22 | 2009-04-27 | Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä |
| US58597109A | 2009-09-29 | 2009-09-29 | |
| PCT/FI2009/051025 WO2010072900A1 (en) | 2008-12-22 | 2009-12-21 | Oncolytic adenoviral vectors and methods and uses related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120039T1 true CY1120039T1 (el) | 2018-12-12 |
Family
ID=44502296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100126T CY1120039T1 (el) | 2008-12-22 | 2017-01-27 | Ογκολυτικοι αδενοϊικοι φορεις και μεθοδοι και χρησεις οι οποιες σχετιζονται με αυτους |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP2379586B1 (enExample) |
| JP (2) | JP2012513209A (enExample) |
| KR (1) | KR101761094B1 (enExample) |
| CN (1) | CN102264760B (enExample) |
| AU (1) | AU2009332883B2 (enExample) |
| BR (1) | BRPI0924123B8 (enExample) |
| CA (1) | CA2748180C (enExample) |
| CY (1) | CY1120039T1 (enExample) |
| DK (1) | DK2379586T3 (enExample) |
| ES (1) | ES2612889T3 (enExample) |
| HR (1) | HRP20170165T1 (enExample) |
| HU (1) | HUE031689T2 (enExample) |
| LT (1) | LT2379586T (enExample) |
| PL (1) | PL2379586T3 (enExample) |
| PT (1) | PT2379586T (enExample) |
| RU (1) | RU2520823C2 (enExample) |
| SG (1) | SG173432A1 (enExample) |
| SI (1) | SI2379586T1 (enExample) |
| WO (1) | WO2010072900A1 (enExample) |
| ZA (1) | ZA201104224B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011070440A2 (en) | 2009-12-10 | 2011-06-16 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| AU2011306846B2 (en) * | 2010-09-24 | 2015-05-14 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| RU2013118723A (ru) * | 2010-09-24 | 2014-10-27 | Онкос Терапьютикс Ой | Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4 |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| US10238698B2 (en) | 2012-01-25 | 2019-03-26 | Dnatrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| RU2019107976A (ru) | 2013-02-21 | 2019-08-23 | Тёрнстоун Лимитед Партнершип | Композиция вакцины |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| EP3461491B1 (en) * | 2013-04-18 | 2024-11-13 | TILT Biotherapeutics Oy | Enhanced adoptive cell therapy |
| US12421502B2 (en) | 2013-04-18 | 2025-09-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| US10350275B2 (en) * | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| CN107849111B (zh) * | 2015-05-04 | 2022-02-22 | Vcn生物科学有限公司 | 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途 |
| FI127460B (en) * | 2016-01-15 | 2018-06-29 | Targovax Oy | Combining adenovirus and chemotherapeutic agents for treating cancer |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| US11497781B2 (en) | 2016-03-10 | 2022-11-15 | Cg Oncology, Inc. | Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor |
| EP3783032A1 (en) | 2016-09-12 | 2021-02-24 | Targovax Oy | Combining adenovirus and checkpoint inhibitors for treating cancer |
| EP3534923A4 (en) | 2016-11-01 | 2020-05-27 | DNAtrix, Inc. | COMBINATION THERAPY FOR THE TREATMENT OF BRAIN CARCINOMAS |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN108261426B (zh) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| WO2018127702A1 (en) | 2017-01-06 | 2018-07-12 | Stabilitech Biopharma Ltd | Virus |
| EP3610026B1 (en) | 2017-04-14 | 2025-05-14 | CG Oncology, Inc. | Cg0070 for treating bcg resistant bladder carcinoma in situ |
| KR20240093758A (ko) | 2017-04-21 | 2024-06-24 | 베이롤 칼리지 오브 메드신 | 종양용해성 바이러스요법 및 면역요법 |
| CA3064897A1 (en) | 2017-05-25 | 2018-11-29 | University Of Central Florida Research Foundation, Inc. | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells |
| EP3708657A4 (en) * | 2017-11-08 | 2021-08-25 | Kagoshima University | ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) THAT IS CAPABLE OF TREATING METASTATIC CANCER ALSO WITH ENSURED SAFETY, WITH EXPRESSION CONTROL SYSTEM THAT BUILDS AN OPTIMAL EXPRESSION LEVEL |
| GB201804473D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| EP3725888A1 (en) * | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase |
| EP3725323A1 (en) | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada |
| EP3725322A1 (en) | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing granzyme and perforin |
| WO2021194183A1 (ko) * | 2020-03-25 | 2021-09-30 | ㈜큐리진 | 면역 회피성 항종양 아데노바이러스 |
| CN111909962A (zh) * | 2020-07-23 | 2020-11-10 | 药鼎(北京)国际细胞医学技术有限公司 | 一种治疗肝癌的病毒构建体及其用途和构建方法 |
| CN118853767A (zh) * | 2024-08-22 | 2024-10-29 | 华中科技大学同济医学院附属同济医院 | 一种新型溶瘤腺病毒载体及其构建方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1135468B1 (en) * | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| ATE291633T1 (de) * | 1999-06-01 | 2005-04-15 | Univ Washington | Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration |
| EP1228234A2 (en) * | 2000-03-14 | 2002-08-07 | Neurologix, Inc. | Production of chimeric capsid vectors |
| WO2005030261A1 (en) * | 2003-08-28 | 2005-04-07 | Cell Genesys, Inc. | Oncolytic adenoviral vectors encoding gm-csf |
| ES2276623B1 (es) * | 2005-12-12 | 2008-06-01 | Proyecto De Biomedicina Cima, S.L | Nuevos adenovirus recombinantes de replicacion condicionada (crad). |
| WO2007103825A2 (en) | 2006-03-02 | 2007-09-13 | The Board Of Regents Of The University Of Texas System | Combination therapy with oncolytic adenovirus |
-
2009
- 2009-12-21 BR BRPI0924123A patent/BRPI0924123B8/pt not_active IP Right Cessation
- 2009-12-21 AU AU2009332883A patent/AU2009332883B2/en not_active Ceased
- 2009-12-21 CA CA2748180A patent/CA2748180C/en active Active
- 2009-12-21 HU HUE09796016A patent/HUE031689T2/en unknown
- 2009-12-21 JP JP2011542856A patent/JP2012513209A/ja active Pending
- 2009-12-21 WO PCT/FI2009/051025 patent/WO2010072900A1/en not_active Ceased
- 2009-12-21 KR KR1020117016272A patent/KR101761094B1/ko not_active Expired - Fee Related
- 2009-12-21 LT LTEP09796016.5T patent/LT2379586T/lt unknown
- 2009-12-21 PT PT97960165T patent/PT2379586T/pt unknown
- 2009-12-21 SG SG2011046109A patent/SG173432A1/en unknown
- 2009-12-21 ES ES09796016.5T patent/ES2612889T3/es active Active
- 2009-12-21 RU RU2011130511/10A patent/RU2520823C2/ru active
- 2009-12-21 EP EP09796016.5A patent/EP2379586B1/en active Active
- 2009-12-21 SI SI200931586A patent/SI2379586T1/sl unknown
- 2009-12-21 HR HRP20170165TT patent/HRP20170165T1/hr unknown
- 2009-12-21 PL PL09796016T patent/PL2379586T3/pl unknown
- 2009-12-21 CN CN200980151762.9A patent/CN102264760B/zh not_active Expired - Fee Related
- 2009-12-21 DK DK09796016.5T patent/DK2379586T3/en active
-
2011
- 2011-06-07 ZA ZA2011/04224A patent/ZA201104224B/en unknown
-
2015
- 2015-08-06 JP JP2015156226A patent/JP6280084B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-27 CY CY20171100126T patent/CY1120039T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110096579A (ko) | 2011-08-30 |
| CN102264760A (zh) | 2011-11-30 |
| ES2612889T3 (es) | 2017-05-19 |
| PL2379586T3 (pl) | 2017-08-31 |
| EP2379586B1 (en) | 2016-11-02 |
| DK2379586T3 (en) | 2017-02-06 |
| AU2009332883A1 (en) | 2011-07-07 |
| CA2748180C (en) | 2017-06-20 |
| JP2012513209A (ja) | 2012-06-14 |
| RU2011130511A (ru) | 2013-01-27 |
| CN102264760B (zh) | 2017-03-22 |
| EP2379586A1 (en) | 2011-10-26 |
| LT2379586T (lt) | 2017-03-10 |
| PT2379586T (pt) | 2017-02-09 |
| HUE031689T2 (en) | 2017-07-28 |
| KR101761094B1 (ko) | 2017-08-04 |
| HRP20170165T1 (hr) | 2017-04-07 |
| AU2009332883B2 (en) | 2015-05-21 |
| RU2520823C2 (ru) | 2014-06-27 |
| JP2016019530A (ja) | 2016-02-04 |
| SI2379586T1 (sl) | 2017-02-28 |
| SG173432A1 (en) | 2011-09-29 |
| WO2010072900A1 (en) | 2010-07-01 |
| JP6280084B2 (ja) | 2018-02-14 |
| CA2748180A1 (en) | 2010-07-01 |
| ZA201104224B (en) | 2012-09-26 |
| BRPI0924123B8 (pt) | 2021-05-25 |
| BRPI0924123B1 (pt) | 2020-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125057T1 (el) | Anti-cd277 αντισωματα και χρησεις αυτων | |
| CY1123010T1 (el) | Διεγερση γονιδιου τrail με μικρο μοριο απο κανονικα και ογκου κυτταρα ως αντικαρκινικη θεραπεια | |
| WO2022120388A3 (en) | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof | |
| MX2018010616A (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| CY1117236T1 (el) | Μονοκλωνικα αντισωματα εναντι γλυπικανης-3 | |
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| CY1121232T1 (el) | Τριαλκυλο κατιονικα λιπιδια και μεθοδοι χρησης αυτων | |
| CY1119219T1 (el) | Anti-ceacam5 αντισωματα και χρησεις αυτων | |
| SA522432139B1 (ar) | بروتينات ربط متعددة الخصوصية لمعالجة السرطان | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| UA111711C2 (uk) | Засіб імунотерапії деяких видів пухлин, у тому числі раку шлунково-кишкового тракту і раку шлунка | |
| BR112013000822A2 (pt) | método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais | |
| CY1114483T1 (el) | Νεα ρυθμιστικα στοιχεια | |
| EA201790862A1 (ru) | Связывающиеся с эритроцитами терапевтические средства | |
| CY1113089T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma) | |
| WO2007041190A3 (en) | Polymer-based delivery system for immunotherapy of cancer | |
| EA201590488A1 (ru) | Способы модификации клеток-хозяев | |
| CY1118949T1 (el) | Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων | |
| CY1122453T1 (el) | Νεα ανοσοθεραπεια εναντι διαφορων ογκων, οπως καρκινος του πνευμονα, οπου συμπεριλαμβανεται nsclc | |
| EP4219536A3 (en) | Targeted/immunomodulatory fusion proteins and methods for making same | |
| CY1119941T1 (el) | Σταθερα και διαλυτα αντισωματα | |
| CA2807942C (en) | Erythrocyte-binding therapeutics | |
| BR112013029834A2 (pt) | vacinas individualizadas para câncer | |
| MY156286A (en) | Human il-23 antigen binding proteins |